cover image: Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome

Premium

20.500.12592/7md8zn

Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome

2011

Compared to clopidogrel, ticagrelor decreases the rate of all-cause mortality, vascular mortality, or myocardial infarction, without an increase in the rate of major bleeding, but with an increase in the risk of major non-CABG bleeding. [...] The benefit of clopidogrel plus aspirin in the prevention of cardiovascular events for NSTEMI-ACS patients was seen in the CURE trial, with a significant risk of major bleeding, compared to aspirin alone. [...] Dual therapy of clopidogrel and aspirin resulted in a 14% reduction in composite endpoint (cardiovascular mortality, MI or stroke), 6% reduction in all- cause mortality, 6% reduction in cardiovascular mortality, 18% reduction in MI, 18% reduction in stroke, and 26% increase in major bleeding; but the incidence of fatal bleeding and hemorrhagic stroke were not increased. [...] The reduction in the rate of non-fatal myocardial infarction was the primary driver of the primary composite endpoints in both PLATO and TRITON. [...] No statistically significant differences were detected between ticagrelor and clopidogrel on the rate of study defined major bleeding within the subgroups.29 The rate of major bleeding varied from 6.2% to 17.4% in the ticagrelor subgroups and 6.5% to 16.4% in the clopidogrel subgroups.29 For ACS patients with planned invasive management (PCI and/or CABG), no data on the rate of bleeding, or non-co
health science and technology research drugs biology cardiovascular system medical research medicine cardiovascular disease therapy coronary artery disease stroke acute coronary syndrome clinical medicine piperazines blood platelets aspirin ticlopidine rcts heart disease health treatment diseases and conditions coronary heart disease pci antiplatelet drug clopidogrel stemi platelet aggregation inhibitors hematologic agents antiplatelet prasugrel ticagrelor adenosine purines purinergic p2y receptor antagonists thiophenes
Pages
31
Published in
Canada

Related Topics

All